Search

Author/Creator Chand, V.K.

1. 3084 Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes. (September 2015)

Authors:
Goss, G.D.; Felip, E.; Cobo, M.; Lu, S.; Syrigos, K.; Li, K.W.; Zhou, C.; Park, K.; Solca, F.; Krämer, N.; Chand, V.K.; Soria, J.C.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S626
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 3085 Second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung: patient-reported outcome (PRO) data from the global LUX-Lung 8 (LL8) Phase III trial. (September 2015)

Authors:
Popat, S.; Felip, E.; Cobo, M.; Fulop, A.; Dayen, C.; Trigo, J.M.; Gregg, R.; Waller, C.F.; Gordon, J.; Lorence, R.; Wang, B.; Chand, V.K.; Hirsh, V.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S626
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search